3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Sarcoma
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Osteosarcoma
3
Leukemia
2
Vomiting
1
Sarcoma, Synovial
1
Sarcoma, Ewing
1
Rhabdoid Tumor
1
Recurrence
1
PRETEXT I Hepatoblastoma
1
Neurofibrosarcoma
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neuroblastoma
1
Nausea
1
Lymphoma, Large-Cell, Anaplastic
1
Localized Extraskeletal Ewing Sarcoma
1
Liposarcoma
1
Leiomyosarcoma
1
Hypersensitivity
1
Histiocytoma, Malignant Fibrous
1
Hemangiosarcoma
1
Ganglioneuroblastoma
1
Fibrosarcoma
1
Extravasations of Anthracycline Anti-cancer Agents
1
Drug-Related Side Effects and Adverse Reactions
1
Dermatofibrosarcoma
1
Degradation of Top2b and Top2a in Human by Dexrazoxane
1
Central Nervous System Neoplasms
1
Interventions
Radiotherapy, Conformal
2
Ifosfamide
2
Doxorubicin
2
romidepsin
1
indolepropanol phosphate
1
etoposide phosphate
1
Watchful Waiting
1
Vincristine
1
Sunitinib
1
Radiotherapy, Intensity-Modulated
1
Radiotherapy
1
Polymerase Chain Reaction
1
Observation
1
Neoadjuvant Therapy
1
Irinotecan
1
HhAntag691
1
Granulocyte Colony-Stimulating Factor
1
Gene Expression Profiling
1
Filgrastim
1
Etoposide
1
Dactinomycin
1
Cyclophosphamide
1
Blotting, Western
1
2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Malignant mesenchymal tumor
×
Dexrazoxane
×
Clear all
No trials found.